MDT

84.09

-0.06%↓

VEEV

226.15

+0.17%↑

A

105.84

-0.02%↓

WBA

10.99

+0.09%↑

CHE

550.42

-2.1%↓

MDT

84.09

-0.06%↓

VEEV

226.15

+0.17%↑

A

105.84

-0.02%↓

WBA

10.99

+0.09%↑

CHE

550.42

-2.1%↓

MDT

84.09

-0.06%↓

VEEV

226.15

+0.17%↑

A

105.84

-0.02%↓

WBA

10.99

+0.09%↑

CHE

550.42

-2.1%↓

MDT

84.09

-0.06%↓

VEEV

226.15

+0.17%↑

A

105.84

-0.02%↓

WBA

10.99

+0.09%↑

CHE

550.42

-2.1%↓

MDT

84.09

-0.06%↓

VEEV

226.15

+0.17%↑

A

105.84

-0.02%↓

WBA

10.99

+0.09%↑

CHE

550.42

-2.1%↓

Search

Vir Biotechnology Inc

Deschisă

SectorSănătate

6.12

Rezumat

Modificarea prețului

24h

Curent

Minim

6

Maxim

6.28

Indicatori cheie

By Trading Economics

Venit

109M

-105M

Vânzări

8.9M

11M

EPS

-0.76

Marjă de profit

-927.372

Angajați

408

EBITDA

97M

-118M

Recomandări

By TipRanks

Recomandări

Puternic Cumpărare

Prognoză pe 12 luni

+462.31% upside

Dividende

By Dow Jones

Următoarele câștiguri

1 mai 2025

Statistici piață

By TradingEconomics

Capitalizare de piață

-530M

775M

Deschiderea anterioară

6.12

Închiderea anterioară

6.12

Scor tehnic

By Trading Central

Încredere

Strong Bullish Evidence

Vir Biotechnology Inc Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

1 nov. 2024, 03:00 UTC

Top știri

U.S. Drugmakers Are Breaking Up With Their Chinese Supply-Chain Partners -- WSJ

Comparație

Modificare preț

Vir Biotechnology Inc Așteptări

Obiectiv de preț

By TipRanks

462.31% sus

Prognoză pe 12 luni

Medie 33.57 USD  462.31%

Maxim 110 USD

Minim 14 USD

În baza a 8 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruVir Biotechnology Inc - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Puternic Cumpărare

8 ratings

7

Cumpărare

1

Păstrare

0

Vânzare

Scor tehnic

By Trading Central

5.54 / N/ASuport & Rezistență

Termen scurt

Strong Bullish Evidence

Termen mediu

Very Strong Bearish Evidence

Termen lung

Bearish Evidence

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre Vir Biotechnology Inc

Vir Biotechnology, Inc., an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company's preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV). The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with MedImmune, LLC; collaboration with WuXi Biologics (Hong Kong) Limited and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with GlaxoSmithKline Biologicals S.A, as well as license agreement with Sanofi for three clinical-stage masked T-cell engagers (TCEs) and exclusive use of the protease-cleavable masking platform for oncology and infectious diseases. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. The company was incorporated in 2016 and is headquartered in San Francisco, California.